Skip to main content

IDEAYA Biosciences, Inc.

corporate_fare Company Profile

IDEAYA Biosciences, Inc.

IDYA·NASDAQ·Life Sciences·CIK 0001676725

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on discovering, developing, and commercializing cancer therapies. The company uses small-molecule drug discovery, structural biology, and bioinformatics, along with internal capabilities in identifying and validating translational biomarkers, to develop targeted therapies aligned with the genetic drivers of disease. IDEAYA Biosciences has a pipeline of product candidates concentrating on synthetic lethality and antibody-drug conjugates (ADCs) for solid tumor indications defined at the molecular level. Their clinical development strategy involves evaluating product candidates in rational combinations and earlier in the course of disease in adjuvant and neoadjuvant settings. The current clinical pipeline includes nine potential first-in-class product candidates across four clinical focus areas: (1) Darovasertib for Uveal Melanoma; (2) ADC and DNA Damage Response (DDR) Combinations; (3) MTAP Pathway; and (4) Next Generation Therapies. The company has collaborations with pharmaceutical companies to support its clinical development activities, including agreements with Pfizer, Servier, Hengrui Pharma, and Gilead. Darovasertib, an oral, potent, and selective small molecule inhibitor of protein kinase C (PKC), is IDEAYA Biosciences' most advanced clinical program. It is being developed for uveal melanoma (UM), a rare and aggressive ocular cancer where approximately 95% of patients have activating mutations in GNAQ/11 GTPase proteins that drive PKC signaling and tumor cell growth. The company is conducting multiple clinical trials for darovasertib in both metastatic and pre-metastatic settings of UM.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for IDYA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 13 rated 8 or above. Recent SEC coverage for IDYA spans 10-Q, 8-K, 424B5.

Recent high-impact activity:

  • IDEAYA Q3: $1.15B Cash, Wider $125.7M Loss, Phase 3 OptimUM-010 Halted
  • IDEAYA Halts Phase 3 Eye Cancer Trial, Frees $100-125M for ADC Push
  • Three ESMO Datasets Back Darovasertib as Foundational Uveal Melanoma Therapy
  • IDEAYA Expands Roche Tie-Up: Genentech to Test IDE892 With KRAS G12D Inhibitor in Pancreatic Cancer
  • IDEAYA Q2 2026: $1.24B Cash Runway, Darovasertib NDA on Track, Pipeline Momentum Builds

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$218.71M
Net Income
-$113.7M
Diluted EPS
-$1.28
Op. Cash Flow
-$71.1M
Free Cash Flow
-$73.47M
Operating Income
-$159.31M
Cash & Equivalents
$112.83M
Debt / Equity
0.00×
Net Margin
-52.0%
Shares Outstanding
87.8M sh
Source: 10-K · filed 2026-02-17 · accession 0001193125-26-054533

Short Interest & Short Volume

8.87 days to cover

FINRA reported short interest of 8,236,480 shares in IDYA as of the October 30, 2026 settlement, a 9.3% decrease from the prior period — about 8.9 days to cover at its recent average daily volume. On November 19, 2026, 41.3% of IDYA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,236,480 shares as of October 30, 2026
Change vs prior period▼ 9.3%
Days to cover8.87 at avg daily volume of 928,512
Daily short volume (FINRA facilities)41.3% of 457,073 shares on November 19, 2026
5-day average short volume39.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for IDYA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.

1 recent capital raise

Public Offering Priced · Significant Discounted Pricing

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$25.69 -1.83% today
52-week range · as of 2026-11-03 $25.69 – $42.68
Market cap
$2.48B
Volume
793.8K (0.7× avg)
3-mo avg 1.1M
Live data · 2026-11-20 20:54 UTC · Market open

show_chartPrice Chart

Loading chart...

feed IDYA - Latest Insights

IDYA
Nov 03, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.36
Real-time Price: $25.69 info
Change: -$5.67 (-18%) info
Market Cap: $2.483B info
IDYA
Nov 03, 2026, 6:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $31.64
Real-time Price: $25.69 info
Change: -$5.95 (-19%) info
Market Cap: $2.483B info
IDYA
Oct 19, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $33.50
Real-time Price: $25.69 info
Change: -$7.81 (-23%) info
Market Cap: $2.483B info
IDYA
Aug 19, 2026, 6:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $37.93
Real-time Price: $25.69 info
Change: -$12.24 (-32%) info
Market Cap: $2.483B info
IDYA
Aug 04, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.11
Real-time Price: $25.69 info
Change: -$10.42 (-29%) info
Market Cap: $2.483B info
IDYA
Aug 04, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.40
Real-time Price: $25.69 info
Change: -$9.71 (-27%) info
Market Cap: $2.483B info
IDYA
Jun 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.60
Real-time Price: $25.69 info
Change: -$1.91 (-7%) info
Market Cap: $2.483B info
IDYA
Jun 10, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $27.60
Real-time Price: $25.69 info
Change: -$1.91 (-7%) info
Market Cap: $2.483B info
IDYA
Jun 09, 2026, 5:16 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $28.07
Real-time Price: $25.69 info
Change: -$2.38 (-8%) info
Market Cap: $2.483B info
IDYA
Jun 08, 2026, 10:24 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $28.91
Real-time Price: $25.69 info
Change: -$3.22 (-11%) info
Market Cap: $2.483B info
IDYA
Jun 08, 2026, 4:13 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $28.95
Real-time Price: $25.69 info
Change: -$3.26 (-11%) info
Market Cap: $2.483B info
IDYA
Jun 08, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $31.48
Real-time Price: $25.69 info
Change: -$5.79 (-18%) info
Market Cap: $2.483B info
IDYA
Jun 03, 2026, 6:25 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $27.42
Real-time Price: $25.69 info
Change: -$1.73 (-6%) info
Market Cap: $2.483B info
IDYA
Jun 03, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.42
Real-time Price: $25.69 info
Change: -$1.73 (-6%) info
Market Cap: $2.483B info
IDYA
Jun 01, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.94
Real-time Price: $25.69 info
Change: -$3.25 (-11%) info
Market Cap: $2.483B info
IDYA
Jun 01, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.94
Real-time Price: $25.69 info
Change: -$3.25 (-11%) info
Market Cap: $2.483B info
IDYA
May 05, 2026, 5:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.80
Real-time Price: $25.69 info
Change: -$3.11 (-11%) info
Market Cap: $2.483B info
IDYA
May 05, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $28.80
Real-time Price: $25.69 info
Change: -$3.11 (-11%) info
Market Cap: $2.483B info
IDYA
May 05, 2026, 6:17 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $28.61
Real-time Price: $25.69 info
Change: -$2.92 (-10%) info
Market Cap: $2.483B info
IDYA
May 05, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.61
Real-time Price: $25.69 info
Change: -$2.92 (-10%) info
Market Cap: $2.483B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets